Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

被引：485

作者：

Hallberg, Bengt ^{[1
]}

Palmer, Ruth H. ^{[1
]}

机构：

[1] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden

来源：

NATURE REVIEWS CANCER | 2013年 / 13卷 / 10期

基金：

瑞典研究理事会;

关键词：

ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; INFLAMMATORY MYOFIBROBLASTIC TUMOR; NPM-ALK; LUNG-CANCER; MOLECULAR CHARACTERIZATION; DOWN-REGULATION; TRUNCATED FORM; GROWTH-FACTOR; FUSION GENE;

D O I：

10.1038/nrc3580

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.

引用

页码：685 / 700

页数：16

共 50 条

[1] The role of the ALK receptor in cancer biology
Hallberg, B.
Palmer, R. H.
ANNALS OF ONCOLOGY, 2016, 27 : 4 - 15
[2] Activation of the orphan receptor tyrosine kinase ALK by zinc
Bennasroune, Aline
Mazot, Pierre
Boutterin, Marie-Claude
Vigny, Marc
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 398 (04) : 702 - 706
[3] Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Murray, Phillip B.
Lax, Irit
Reshetnyak, Andrey
Ligon, Gwenda F.
Lillquist, Jay S.
Natoli, Edward J., Jr.
Shi, Xiarong
Folta-Stogniew, Ewa
Gunel, Murat
Alvarado, Diego
Schlessinger, Joseph
SCIENCE SIGNALING, 2015, 8 (360)
[4] Characterization of the expression of the ALK receptor tyrosine kinase in mice
Vernersson, E
Khoo, NKS
Henriksson, ML
Roos, G
Palmer, RH
Hallberg, B
GENE EXPRESSION PATTERNS, 2006, 6 (05) : 448 - 461
[5] The neuronal receptor tyrosine kinase Alk is a target for longevity
Woodling, Nathaniel S.
Aleyakpo, Benjamin
Dyson, Miranda Claire
Minkley, Lucy J.
Rajasingam, Arjunan
Dobson, Adam J.
Leung, Kristie H. C.
Pomposova, Simona
Fuentealba, Matias
Alic, Nazif
Partridge, Linda
AGING CELL, 2020, 19 (05)
[6] Receptor tyrosine kinase inhibitors in cancer
Ebrahimi, Nasim
Fardi, Elmira
Ghaderi, Hajarossadat
Palizdar, Sahar
Khorram, Roya
Vafadar, Reza
Ghanaatian, Masoud
Rezaei-Tazangi, Fatemeh
Baziyar, Payam
Ahmadi, Amirhossein
Hamblin, Michael R.
Aref, Amir Reza
CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (04)
[7] Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
Choi, Se Hoon
Kim, Dong Ha
Choi, Yun Jung
Kim, Seon Ye
Lee, Jung-Eun
Sung, Ki Jung
Kim, Woo Sung
Choi, Chang-Min
Rho, Jin Kyung
Lee, Jae Cheol
ONCOTARGET, 2017, 8 (35) : 58771 - 58780
[8] Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Huang, Hao
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
[9] Patterns of ALK expression in different human cancer types
Tennstedt, Pierre
Strobel, Gundula
Boelch, Charlotte
Grob, Tobias
Minner, Sarah
Masser, Sawinee
Simon, Ronald
JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (06) : 477 - 481
[10] ALECTINIB HYDROCHLORIDE ALK Receptor Tyrosine Kinase Inhibitor Oncolytic
Cole, P.
DRUGS OF THE FUTURE, 2013, 38 (12) : 799 - 805

← 1 2 3 4 5 →